CD274 and lung carcinoma: Regimen‐specific patterns developed: PD‐1 inhibitors were mainly applied to NSCLC and metastatic malignancies, whereas PD‐L1 inhibitors were more broadly used in relation to SCLC and extensive‐stage SCLC and end‐stage lung cancers.